These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 35653428)

  • 1. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.
    Najjar-Debbiny R; Gronich N; Weber G; Khoury J; Amar M; Stein N; Goldstein LH; Saliba W
    Clin Infect Dis; 2023 Feb; 76(3):e342-e349. PubMed ID: 35653428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022.
    Kim JM; Yoo MG; Bae SJ; Kim J; Lee H
    J Korean Med Sci; 2023 Jul; 38(27):e211. PubMed ID: 37431541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis.
    Najjar-Debbiny R; Gronich N; Weber G; Khoury J; Amar M; Stein N; Goldstein LH; Saliba W
    Clin Infect Dis; 2023 Feb; 76(3):453-460. PubMed ID: 36130189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study.
    Hansen K; Makkar SR; Sahner D; Fessel J; Hotaling N; Sidky H
    medRxiv; 2023 Jun; ():. PubMed ID: 37398261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the use of Paxlovid in clinical practice.
    McCarthy MW
    Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
    Razonable RR; O'Horo JC; Hanson SN; Arndt RF; Speicher LL; Seville TA; Hall ST; Pike ML; Heyliger A; Larsen JJ; Ganesh R; Tulledge-Scheitel SM
    J Infect Dis; 2022 Nov; 226(10):1683-1687. PubMed ID: 36124696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.
    Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paxlovid for Treating COVID-19 Patients: A Case-Control Study From Two Hospitals in the Eastern Province of Saudi Arabia.
    Alsaeed A; Alkhalaf A; Alomran A; Alsfyani W; Alhaddad F; Alhaddad MJ
    Cureus; 2023 May; 15(5):e39234. PubMed ID: 37337482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022.
    Shah MM; Joyce B; Plumb ID; Sahakian S; Feldstein LR; Barkley E; Paccione M; Deckert J; Sandmann D; Gerhart JL; Hagen MB
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1531-1537. PubMed ID: 36454693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study.
    Wang W; Wang YH; Huang CH; Hsieh TH; Ibarburu GH; Wei JC
    BMC Med; 2024 Mar; 22(1):117. PubMed ID: 38481216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2.
    Park H; Park YJ; Lee HY; Yu M; Song YJ; Lee SE; Lee JJ; Lee ES; Kim Y
    Osong Public Health Res Perspect; 2022 Dec; 13(6):443-447. PubMed ID: 36617550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study.
    Qiu Y; Wen H; Wang H; Sun W; Li G; Li S; Wang Y; Zhai J; Zhan Y; Su Y; Long Z; Li Z; Ye F
    Front Pharmacol; 2024; 15():1401658. PubMed ID: 39224781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
    Dawood AA
    Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of nirmatrelvir/ritonavir (Paxlovid®) in preventing hospitalisation and death among COVID-19 patients: a prospective cohort study.
    Chew LS; Lim XJ; Chang CT; Kamaludin RS; Leow HL; Ong SY; Saharuddin N; Sanusi NA; Kamaruzaman N; Kamarruddin Z; Philip R
    Med J Malaysia; 2023 Sep; 78(5):602-608. PubMed ID: 37775486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report.
    Zhang L; Zhang S; Han J; Yi Y; Zhou H; Li J
    Medicine (Baltimore); 2022 Nov; 101(45):e31361. PubMed ID: 36397388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients - A Large-Scale Observational Cohort Study from the RECOVER Initiative.
    Wang F; Zang C; Li H; Khullar D; Zhang Y; Strobel S; Chen Y; Sala M; Patel P; Comellas A; Wylam A; Weiner M; Forrest C; Carton T; Kaushal R
    Res Sq; 2024 Jun; ():. PubMed ID: 38947026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.